Vivos Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript
Vivos Therapeutics, Inc. (VVOS) Q2 2026 Earnings Call Transcript
Vivos Therapeutics Q2 EPS $(0.31) Beats $(0.36) Estimate, Sales $5.153M Miss $5.367M Estimate
Vivos Therapeutics Expands Greenway Health AI Partnership, Could Create Up To $9M In Potential Annual Value
Vivos Therapeutics Has Been Granted U.S. Patent Number 12,697,190 Titled "VIBRATIONAL ORAL APPLIANCE WITH MANDIBULAR ADVANCEMENTS"
Vivos Therapeutics' Bradford Amman Resigns As CFO; Roman Franklin Appointed As Chief Financial Officer
Vivos Therapeutics Announces Its Treatment With ITS FDA-Cleared Vida Oral Appliance Demonstrates Enhancement In Insomnia Severity In 100% Of Patients In Trial
Vivos Extends Streeterville Financing Deal Through Aug. 31, Reaffirms Plan To Convert Up To $4.5M Debt Into Preferred And Common Stock
Vivos Therapeutics Announces Intent To File Registration For Proposed Rights Offering
Vivos Therapeutics Partners With South Palm Cardiovascular Associates To Form, Operate Physician-Aligned Management Services Organization AIM Florida
Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026
Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing
Vivos Therapeutics Enters Senior Debt-to-Equity Exchange Agreement With Streeterville Capital For Up To $4.5M
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Raises Price Target to $3.1
Vivos Therapeutics Inc (VVOS) Q1 2026 Earnings Call Highlights: Revenue Surges Amid Strategic Shifts
Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call Transcript
Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update
Vivos Therapeutics Q1 EPS $(0.52) Misses $(0.45) Estimate, Sales $5.141M Beat $4.225M Estimate
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $3
New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM EST - Show #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Group Holding (NASDAQ:YYGH), and Vivos Therapeutics (NASDAQ:VVOS)
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.